Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • Tonix Pharmaceuticals Holding's Gains from Investment Securities changed N/A to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $3865.0 for FY2024, which is 39935.4% up from last year.
  • Tonix Pharmaceuticals Holding's Gains from Investment Securities amounted to $1.2 million in Q3 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Gains from Investment Securities peaked at $9.7 million during Q1 2024, and registered a low of $774.0 during Q4 2023.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Gains from Investment Securities averaged around $2.7 million, with its median value being $1.2 million (2025).
  • Over the last 5 years, Tonix Pharmaceuticals Holding's Gains from Investment Securities had its largest YoY gain of 27126.19% in 2025, and its largest YoY loss of 9308.57% in 2025.
  • Tonix Pharmaceuticals Holding's Gains from Investment Securities (Quarter) stood at $774.0 in 2023, then soared by 40054.65% to $310797.0 in 2024, then surged by 272.54% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.2 million for Q2 2025, and $674134.0 during Q1 2025.